ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0872

Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)

Sudha Raghunath1, Yifat Glikmann-Johnston1, Emma Guymer1, Eric Morand2, Julie Stout1 and Alberta Hoi3, 1Monash University, Melbourne, Australia, 2School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, 3Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia

Meeting: ACR Convergence 2021

Keywords: Anxiety, Cognitive dysfunction, depression, fibromyalgia, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive function in SLE, but the associations of fibromyalgia with these are unclear. We investigated the relationships between patient-reported cognitive symptoms and objective cognitive test results in SLE, and associations of fibromyalgia and mood disorders with both.

Methods: We tested SLE patients (n=87) and demographically matched healthy control (HC) participants (n=48) with the one-hour neuropsychiatric test battery recommended by the ACR for use in SLE (2) and applied three binary definitions of CD and seven cognitive test z-scores. We assessed patient-reported cognitive symptoms, mood disorder symptoms, fibromyalgia symptoms, and fatigue using the Cognitive Symptoms Inventory (CSI), Hospital Anxiety and Depression Scale (HADS), Central Sensitivity Score (CSS) derived from the 2016 ACR fibromyalgia diagnostic criteria (3) and the Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT), respectively. We performed multivariate regression analysis to determine associations with cognitive endpoints; likelihood ratio tests were used to select for inclusion from collinear pairs. We used unpaired t tests to compare CSI scores between groups.

Results: Among SLE patients, the median (range) age was 45 (22-64). Compared to HC, CSS scores were higher (< 0.00001), fibromyalgia was more common (p 0.009) and a history of depression or anxiety was more frequent (p< 0.0001) in SLE patients (Table 1). Cognitive symptoms (CSI score) were worse in SLE patients than HC (median (range) 33 (19-52) vs. 26.5 (21-35), p < 0.0001). At all thresholds, cognitive dysfunction was also more frequent in SLE patients than HC. Age and premorbid IQ were significantly associated with multiple cognitive test endpoints but not with CSI score. On multivariate analysis, CSS, a history of depression, and HADS Anxiety each had significant associations with at least one CD endpoint, but history of anxiety or FACIT score did not. On univariate analysis, cognitive symptoms (CSI) consistently correlated with CSS, FACIT and all mood disorder covariates (CSI) (p 0.02 - < 0.001); on multivariate analysis, after selecting from collinear pairs, only CSS remained significant (p< 0.0001) (Table 2). There were no associations between cognitive symptoms and cognitive test results. Correspondingly, there was no significant difference in cognitive symptoms (CSI score) between cognitively impaired and unimpaired SLE patients at any cognitive impairment threshold (p values 0.22-0.47).

Conclusion: Cognitive impairment, and cognitive symptoms, are each common in patients with SLE, but there were no associations between patient-reported cognitive symptoms and objective cognitive test results. Depression, anxiety and fibromyalgia were more strongly associated with cognitive symptoms than with test results. The distinction between cognitive symptoms and cognitive function needs to be considered when assessing SLE patients with CD.

References: 1) Al Rayes et al. Semin Arthritis Rheum 2018. 2) Liang et al. Arthritis Rheum 1999. 3) Wolfe et al. Semin Arthritis Rheum 2016.

Table 1: Characteristics of Study Groups.
1) Sociodemographic variables were compared between the SLE and control groups using Mann-Whitney, Chi squared and T tests. 2) Premorbid IQ measured by Test of Premorbid Functioning scaled score. 3) HADs – Hospital Anxiety and Depression Scale. 4) Central Sensitivity Score = Widespread Pain Index plus Symptom Severity Score as per 2016 ACR Fibromyalgia Diagnostic Criteria. 5) Meeting 2016 ACR Fibromyalgia Diagnostic Criteria. 6) Impairment defined by number of cognitive domains either 1.5 or 2 standard deviations (SD) below healthy control group mean.

Table 2: Multivariate Analysis of Mood Disorders, Fibromyalgia and Cognitive Test Results and Symptoms in SLE.
Significant results bolded: *p value <0.05 **p value <0.005.
1) Impairment defined by number of cognitive domains either 1.5 or 2 SD below healthy control group mean. 2) Specific cognitive tests used for each domain are as follows: Visual Memory – Rey Ostrrieth Complex Figure Test Recall Score, Verbal Memory -California Verbal Learning Test trials 1-5, Verbal Fluency – Controlled Oral Word Association Test FAS Sum, Working Memory – Letter Number Sequencing score, Processing Speed – Coding score, Complex Attention – Trail making test B time inverse, Psychomotor speed – finger tap test dominant hand score. 3) for FACIT scores higher scores represent less fatigue (better functioning). Acronyms: TIA – transient ischaemic attack, CSS – Central Sensitivity Score derived from 2016 Fibromyalgia diagnostic criteria, HADS – Hospital Anxiety and Depression Scale, FACIT – Functional Assessment of Chronic Illness Therapy Fatigue Scale. CSI – Cognitive Symptoms Inventory, SD – standard deviations.


Disclosures: S. Raghunath, None; Y. Glikmann-Johnston, None; E. Guymer, None; E. Morand, Amgen, 2, AbbVie, 2, Biogen, 2, Bristol Myers Squibb, 2, 5, AstraZeneca, 2, 5, 6, Genentech, 2, Servier, 2, Capella Biosciences, 2, Eli Lilly, 5, 6, EMD Serono, 5, 6, Janssen, 2, 5, UCB, 2, GlaxoSmithKline, 2, 5; J. Stout, Zindametrix, Pty Ltd, 4; A. Hoi, AstraZeneca, 2, 5, Janssen, 6, Abbvie, 6.

To cite this abstract in AMA style:

Raghunath S, Glikmann-Johnston Y, Guymer E, Morand E, Stout J, Hoi A. Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/lack-of-association-between-cognitive-test-performance-and-cognitive-symptoms-in-systemic-lupus-erythematosus-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-association-between-cognitive-test-performance-and-cognitive-symptoms-in-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology